Olezarsen Lowers Triglycerides by 60%
Here’s a summary of the key findings from the article about olezarsen, as reported in The New England Journal of Medicine:
Key Findings:
Meaningful Triglyceride Reduction: Olezarsen (50mg and 80mg doses) considerably reduced triglyceride levels compared to placebo after 6 months (-58.4% and -60.6% respectively, P < .001).
Normalization of Triglycerides: A much higher percentage of patients on olezarsen achieved normal triglyceride levels (<150 mg/dL) compared to placebo (85% and 88.7% vs. 12.5%, P < .001). This was specifically observed in patients with moderate hypertriglyceridemia.
Improved Lipid Profile: Olezarsen treatment also led to reductions in non-HDL cholesterol (up to 22%), VLDL cholesterol (57%), remnant cholesterol (68%), and ApoB (15%). Importantly,LDL cholesterol levels remained unchanged.
Safety: The treatment appeared safe, with similar rates of adverse and serious adverse events between the olezarsen groups and the placebo group. Injection-site reactions were more common with olezarsen, but increases in liver enzymes were rare.
Future research Needed: The researchers acknowledge that further trials are needed to determine if these lipid profile improvements translate into actual cardiovascular benefits.
Study Details:
Published in: The New England Journal of Medicine
Presented at: European Society of Cardiology Congress, August 29-September 1, 2025, Madrid.
Funding: The study (Essence-TIMI 73b trial) was funded by Ionis Pharmaceuticals.